Skip to main content
. 2011 May 10;5:255–274. doi: 10.2147/DDDT.S10498

Table 2.

Using data from placebo groups over 2 years based on 100 subjects in each group to predict the number of expected relapses

Efficacy Relapse reduction 30% 30% 50% 70%
Example therapy IFN-β, GA terifluonamide cladribine/fingolimod natalizumab/mitoxantrone
Side effects (%) serious 0 0.1 0.8/0.8 0.1/0.7
ongoing 80% minimal minimal minimal
Expected relapses with therapy over 2 years
Demyelination syndrome subtype (expected relapses in 2 year period) Rapidly evolving severe (300) graphic file with name dddt-5-255i1.jpg
Clinically definite – group 1 (240)
Clinically definite – group 2 (100)
McDonald (41)
CIS ≥ 3 MRI lesions (45)
<3 MRI lesions (10)
RIS (31)

Notes: Using trial efficacy data the relapses that will occur as result of therapy can be predicted. Acceptability is highlighted: green, acceptable in most health systems; orange: acceptable in US/parts of Europe; red: not acceptable in health systems due to side effects; grey outline: groups in trials that have been tested.

Abbreviations: CIS, clinically isolated syndrome; RIS, radiologically isolated syndrome; GA, glatiramer acetate.